Review Article

Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Dong Wei, 1 Yunchao Xin, 2 Yu Rong, 1 and Yanbing Hao 1

1 Department of Thoracic Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China
2 Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China

Correspondence should be addressed to Yanbing Hao; haornwakcm570@163.com

Received 15 May 2022; Revised 27 May 2022; Accepted 30 May 2022; Published 28 June 2022

Academic Editor: Tian Jiao Wang

Copyright © 2022 Dong Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Lymph node metastasis is the most common and important way of metastasis in NSCLC and is also the most important factor affecting lung cancer stage and prognosis. It is very important to analyze the relationship between the expression of vascular endothelial growth factor (VEGF) and Ki67 and lymph node metastasis (LNM) in non-small-cell lung cancer (NSCLC).

Methods. We searched the PubMed, EMBASE, and Cochrane Library and conducted meta-analyses using the R meta-package. Relative risk (RR) with a 95% confidence interval (95% CI) was the main indicator.

Results. Totally, 18 studies were considered eligible, with 4521 patients, including 1518 LNM-positive patients and 3033 LNM-negative patients. The incidence of LNM in Ki67-negative patients was lower than that in Ki67-positive patients (RR = 0.66, 95% CI: 0.44, 0.98). The incidence of LNM in VEGF-A-negative patients was lower than that in VEGF-A-positive patients (RR = 0.64, 95% CI: 0.49, 0.83). The incidence of LNM in VEGF-C negative patients was lower than that in VEGF-C positive patients (RR = 0.68, 95% CI: 0.53, 0.88). The incidence of LNM in VEGF-D negative and positive patients were of no significant differences (RR = 0.84, 95% CI: 0.61, 1.14).

Conclusion. The high expression of Ki67, VEGF-A, and VEGF-C significantly increases the risk of lymph node metastasis in NSCLC, while the VEGF-D expression has no correlation with lymph node metastasis. The expression levels of Ki67, VEGF-A, and VEGF-C show a good potential for lymph node metastasis prediction.

1. Introduction

Lung cancer is a tumor that originates from the bronchial mucosa or glands of the lungs, and the confirmed cases approached 1.8 million in year 2012, and the death toll was about 1.6 million [1]. Statistics show that there were 230,000 new cases in the United States alone in 2018, and lung cancer-related deaths exceed the sum of breast, prostate, and colon cancer-related deaths [2, 3]. In recent years, despite major progress in lung cancer treatment with respect to risk factors determination, disease progression detection, and immune control approach, the disease is the leading cause of cancer death because of the insidious symptoms and the lack of effective screening methods [4, 5]. Non-small-cell lung cancer (NSCLC) is a common type of lung cancer and includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [6]. Within contrast to small cell carcinoma, NSCLC features slow cells growth and division and late spread and metastasis [7]. Lymph node metastasis is an essential link in tumor progression, indicating that the tumor transforms from local to invasive type [8]. In contrast to patients with the same tumor size but without lymph node metastasis, those with lymph node metastasis experience a grimmer prognosis [9].

Ki-67 is a cell proliferation-associated antigen that is expressed in the nucleus and closely linked to mitosis and integrally embodies the cell proliferation activity. Its function is correlated with cell mitosis and cell cycle [10]. Ki67 marks cells in the growth cycle, and the higher positive rate indicates larger proportion of tumor cells in the growth
Evidence-Based Complementary and Alternative Medicine

2. Methods

2.1. Search Strategy and Selection Criteria. In this study, we searched the PubMed, EMBASE, and Cochrane Library from the date of their inception to March 13, 2022. We used the search terms (Ki67 (Title/Abstract)) or (VEGF (Title/Abstract) or (vascular endothelial growth factor (Title/Abstract)) and ((non-small-cell lung cancer) (Title/Abstract) or NSCLC (Title/Abstract)), with a language restriction of English. The reference lists of all included articles and all pertinent review articles herein were reviewed to identify articles that may have been missed.

2.2. Inclusion and Exclusion Criteria of Literature. Inclusion criteria were as follows: (1) study type: randomized comparison clinical trial (RCT), observational study, or clinical trial; (2) study object: pathologically diagnosed NSCLC; (3) the study data include lymph node status (whether lymph node metastasis occurs or not), Ki67, and VEGF levels; (4) the study design is scientific and standardized, and the follow-up data and other data are complete; and (5) Ki67, VEGF-A, VEGF-C, and VEGF-D are evaluated by ELISA, immunohistochemistry, or flow cytometry.

Exclusion criteria were as follows: (1) case reports, reviews, or in vitro studies; (2) no lung cancer staging; and (3) less than 20 patients were included.

2.3. Quality Assessment. Two reviewers screened the search results, retrieved full text articles, checked inclusion criteria, and eliminated duplicate literature from three levels of article title, abstract, and full text, and then decided the included articles of this study. The Newcastle–Ottawa Scale was adopted to evaluate the quality of the eligible literature, and if consensus was not reached, a third reviewer was involved.

2.4. Data Extraction. Data extraction was performed by two investigators independently, and the data were entered in electronic forms including first author name, publication year, tumor stage, number of subjects, lymph node metastasis status, Ki 67 expression, VEGF expression, and other results. Among them, the primary meta-analysis outcomes of interest were the incidence of lymph node metastasis in cases with different Ki 67 and VEGF expression.

2.5. Statistical Analysis. We conducted meta-analyses using the R meta-package. Data extraction was (sample size) and the number of target indicators was (case). We estimated the heterogeneity via $I^2$ test ($I^2 > 0$ or $P$ value $<$ 0.1 indicated heterogeneity, and a random-effects model of analysis was used; $I^2 = 0.01$, $P$ value $>$ 0.1 indicated the absence of significant heterogeneity, and a fixed-effects model of analysis was used). 95% CIs for the cumulative risks were calculated with the risk estimates provided, applying a dichotomic variable analysis.

3. Results

3.1. Literature Search and Intervention Studies. Our search yielded 2685 citations, which were initially screened on the abstract level for eligibility. After reading the full text, 18 studies [19–36] including 4521 patients were deemed eligible (1518 LNM-positive patients and 3033 LNM-negative patients). The literature screening flowchart is displayed in Figure 1, and the descriptive details of the eligible studies are provided in Table 1. The risk of literature bias is displayed in Figure 2, suggesting a high quality of the included literature.

3.2. Ki67 Expression Level and Incidence of LNM. A total of 5 literature analyzed the incidence of LNM in patients with different Ki67 expression levels, including 396 Ki67-negative patients and 2588 positive patients. The results showed significant heterogeneity among the studies ($I^2 = 72\%$, $P < 0.01$) using a random-effects model. The incidence of LNM in Ki67-negative patients was lower than that in Ki67-positive patients (RR = 0.66, 95% CI: 0.44, 0.98), indicating that Ki67-positive expression can increase the incidence of LNM (Figure 3).
Records identified database searching (n = 2685)
Additional records identified by other sources (n = 146)
Records after duplicates removed (n = 2146)
Record screened (n = 83)
Full-text records assessed for eligibility (n = 34)
Study included (n = 18)

**Figure 1:** Literature screening flowchart.

**Table 1:** Descriptive details of the included trials.

| Author                | Year | Stage    | LNM-positive | LNM-positive | Outcome       |
|-----------------------|------|----------|--------------|--------------|---------------|
| He et al. [19]        | 2016 | Undeclared | 43           | 25           | Ki 67         |
| Xue et al. [20]       | 2020 | Resected NSCLC | 779         | 1844         | Ki 67         |
| Ji et al. [21]        | 2014 | I–III    | 40           | 17           | Ki 67         |
| Yang et al. [22]      | 2006 | I–IIia   | 46           | 81           | Ki 67         |
| Ahn et al. [23]       | 2014 | I–III    | 49           | 60           | Ki 67         |
| Adachi et al. [24]    | 2007 | Resected NSCLC | 17           | 59           | VEGF-C, VEGF-C|
| Donnem et al. [25]    | 2009 | I–IIia   | 102          | 232          | VEGF-A, VEGF-C, VEGF-D |
| Feng et al. [26]      | 2010 | I–IIia   | 42           | 54           | VEGF-C, VEGF-D |
| Guo et al. [27]       | 2009 | I–IV     | 34           | 31           | VEGF-C         |
| Iwakiri et al. [28]   | 2001 | I–IV     | 25           | 37           | VEGF-C         |
| Kojima et al. [29]    | 2005 | I–III    | 24           | 105          | VEGF-C         |
| Nakashima et al. [30] | 2004 | I–IIIb   | 47           | 106          | VEGF-A, VEGF-C |
| Ogawa et al. [31]     | 2004 | I–IIIb   | 71           | 135          | VEGF-C         |
| Renyi-Vamos et al. [32]| 2005 | I–IIia  | 42           | 47           | VEGF-C         |
| Saintigny et al. [33] | 2007 | I–III    | 45           | 47           | VEGF-C         |
| Takanami [34]         | 2006 | I–IIia   | 30           | 47           | VEGF-C         |
| Zuo et al. [35]       | 2008 | I–III    | 16           | 32           | VEGF-C         |
| Bi et al. [36]        | 2017 | I–IV     | 66           | 44           | VEGF-C         |

**Figure 2:** Included literature quality evaluation chart.
3.3. VEGF Expression and Incidence of LNM

3.3.1. VEGF-A Expression and Incidence of LNM. A total of 2 literature analyzed the incidence of LNM in patients with different VEGF-A expression levels, including 267 VEGF-A-negative patients and 220 positive patients. No significant heterogeneity was seen between studies ($I^2 = 0$, $P = 0.94$) using a fixed-effects model. The incidence of LNM in VEGF-A-negative patients was lower than that in VEGF-A-positive patients (RR = 0.64, 95% CI: 0.49, 0.83), indicating that VEGF-A positive expression can increase the incidence of LNM (Figure 4).

3.3.2. VEGF-C Expression and Incidence of LNM. A total of 13 pieces of literature analyzed the incidence of LNM in patients with different VEGF-C expression levels, including 811 VEGF-C-negative patients and 727 positive patients. Significant heterogeneity existed among studies ($I^2 = 61\%$, $P < 0.01$), using a random-effects model. The incidence of LNM in VEGF-C negative patients was lower than that in VEGF-C positive patients (RR = 0.68, 95% CI: 0.53, 0.88), indicating that VEGF-C positive expression can increase the incidence of LNM (Figure 5).

3.3.3. VEGF-D Expression and Incidence of LNM. A total of 3 literature analyzed the incidence of LNM in patients with different VEGF-D expression levels, including 211 VEGF-D-negative patients and 294 positive patients. There was no significant heterogeneity among studies ($I^2 = 0\%$, $P = 0.68$), using a fixed-effects model. No significant difference in the incidence of LNM between VEGF-D-negative and positive patients was seen (RR = 0.84, 95% CI: 0.61, 1.14) (Figure 6).

3.4. Publication Bias Analysis. The funnel plot of the meta-analysis of the incidence of LNM at different expression levels of Ki67, VEGF-A, VEGF-C, and VEGF-D is shown in Figure 7. The funnel plot of the Ki67 analysis was significantly asymmetric, and the scatter points of the other three studies were distributed on both sides of the inverted funnel plot, which was basically symmetrical, indicating a small possibility of publication bias in this study.

4. Discussion

Despite the recent progress in immunotherapy and targeted therapy in lung cancer, multiple emerging targeted therapy drugs being approved for marketing, and the expanded indications of targeted therapy, lung cancer constitutes the highest mortality in China [37, 38]. In 2017, lung cancer in China ranked first among male patients, accounting for 23.01% of all cancers, and second only to breast cancer in female patients, with an incidence of 14.85% [39]. Lymph node metastasis is the major content of TMN staging and a key approach to determine treatment options and evaluate clinical prognosis [40, 41]. However, lymph node metastasis is not only related to tumor diameter, depth of invasion, and histological type, but also to factors such as Ki67 and VEGF [42].

Here, the incidence of LNM in Ki67-negative patients was lower than in Ki67-positive patients and the expression level of Ki67 was closely related to lymph node metastasis in NSCLC patients. Ki-67, an indirect method for detecting the proliferation of cells, reflects the proliferation ability of tumor cells and it is solely expressed in proliferating cells [43]. Studies have confirmed that lung cancer cells with a positive expression of Ki-67 have significantly increased proliferation activity, stronger invasive ability, and are more prone to lymph node metastasis. In the NSCLC cohort, Ki67 expression was positively correlated with male sex, lymph node metastasis, larger tumor (>4 cm), advanced stage (stage III + IV), smoking, and tumor differentiation [44]. In addition, the overexpression of Ki67 is closely related to circulating tumor cell epithelial-mesenchymal transition (CTC EMT), and the positive rate of CTC EMT in patients with a high Ki67 expression is significantly increased [45]. In addition, significant heterogeneity was found in the analysis of the relationship between Ki67 levels and the incidence of LNM. This finding might be attributed to the fact that although Ki-67 is a powerful and valuable biomarker of cell proliferation, the clinical value of the assay is hampered by variability in the degree of measurement and lack of standardization across different types of specimens, and it possibly explains the presence of heterogeneity in this study [46]. In this regard, defining the detection method and determining the detection standard are the key links to be addressed during the clinical use of Ki67.

Additionally, the incidence of LNM in VEGF-A-negative patients was lower than that in VEGF-A-positive patients; the incidence of LNM in VEGF-C-negative patients was lower than that in VEGF-C-positive patients; the difference in the incidence of LNM between VEGF-D negative and positive patients did not come up to the statistical standard. All these findings suggest a good potential of the expression levels of VEGF-A–C to predict lymph node metastasis. Similar to our findings, prior research considered VEGF as a specific vascular endothelial cell growth factor to the division and

| Ki67 | Ki67 (-) LNM (+) Total | Ki67 (+) LNM (+) Total | Risk Ratio | RR | 95%-CI | Weight |
|------|------------------------|------------------------|------------|---------|-----------------|---------|
| He LY--2016 | 11 26 32 42 | | 0.56 [0.34; 0.90] | 20.3% |
| Xue X--2020 | 28 235 751 2388 | | 0.38 [0.27; 0.54] | 23.4% |
| Ji Y--2014 | 9 18 31 39 | | 0.63 [0.39; 1.03] | 20.1% |
| Yang J--2006 | 10 28 36 99 | | 0.98 [0.56; 1.72] | 18.3% |
| Ahn HK--2014 | 41 89 8 20 | | 1.15 [0.64; 2.06] | 17.9% |

Random effects model 396 2588 0.66 [0.44; 0.98] 100.0%
| VEGF-A | VEGF-A (-) | VEGF-A (+) | Risk Ratio | RR | 95%-CI | Weight |
|--------|-----------|-----------|------------|----|--------|--------|
| LMN (+) | Total | LMN (-) | Total |
| Donnem T--2009 | 47 | 192 | 55 | 142 | 0.63 | [0.46; 0.87] | 70.1% |
| Nakashima T--2009 | 18 | 75 | 29 | 78 | 0.65 | [0.39; 1.06] | 29.9% |
| Common effects model | 267 | 220 | | | 0.64 | [0.49; 0.83] | 100.0% |
| Heterogeneity: $I^2 = 0$, $p = 0.68$ |

Figure 4: Forest plot of the VEGF-A expression level and incidence of LNM.

| VEGF-C | VEGF-C (-) | VEGF-C (+) | Risk Ratio | RR | 95%-CI | Weight |
|--------|-----------|-----------|------------|----|--------|--------|
| LMN (+) | Total | LMN (-) | Total |
| Adachi Y--2007 | 10 | 61 | 7 | 15 | 0.35 | [0.16; 0.77] | 61.0% |
| Donnem T--2009 | 68 | 231 | 35 | 104 | 0.87 | [0.63; 1.22] | 11.3% |
| Feng Y--2010 | 19 | 52 | 23 | 44 | 0.70 | [0.44; 1.10] | 9.7% |
| Guo X--2009 | 1 | 15 | 33 | 50 | 0.10 | [0.02; 0.68] | 1.6% |
| Kajita T--2001 | 11 | 38 | 14 | 24 | 0.50 | [0.27; 0.91] | 7.9% |
| Kojima H--2005 | 10 | 73 | 14 | 56 | 0.55 | [0.26; 1.14] | 6.5% |
| Nakashima Y--2004 | 28 | 89 | 19 | 64 | 1.06 | [0.65; 1.72] | 9.3% |
| Ogawa E--2004 | 29 | 81 | 42 | 125 | 1.07 | [0.73; 1.56] | 10.7% |
| Renyi Vamos F--2005 | 30 | 55 | 12 | 34 | 1.55 | [0.92; 2.59] | 9.0% |
| Santigny P--2007 | 8 | 24 | 37 | 68 | 0.61 | [0.33; 1.12] | 7.9% |
| Takami Y--2006 | 6 | 31 | 24 | 40 | 0.37 | [0.17; 0.80] | 6.2% |
| Zuo S--2008 | 2 | 15 | 14 | 33 | 0.31 | [0.08; 1.21] | 2.9% |
| Bi MM--2017 | 20 | 46 | 46 | 64 | 0.60 | [0.42; 0.87] | 10.9% |
| Random effects model | 811 | 727 | | | 0.68 | [0.53; 0.88] | 100.0% |
| Heterogeneity: $I^2 = 61\%$, $p = 0.123$ |

Figure 5: Forest plot of the VEGF-C expression level and incidence of LNM.

| VEGF-D | VEGF-D (-) | VEGF-D (+) | Risk Ratio | RR | 95%-CI | Weight |
|--------|-----------|-----------|------------|----|--------|--------|
| LMN (+) | Total | LMN (-) | Total |
| Adachi Y--2007 | 10 | 53 | 6 | 22 | 0.69 | [0.29; 1.67] | 12.7% |
| Donnem T--2009 | 28 | 106 | 75 | 228 | 0.80 | [0.56; 1.16] | 71.1% |
| Feng Y--2010 | 13 | 52 | 10 | 44 | 1.10 | [0.54; 2.26] | 16.2% |
| Common effect model | 211 | 294 | | | 0.84 | [0.62; 1.14] | 100.0% |
| Heterogeneity: $I^2 = 0$, $p = 0.68$ |

Figure 6: Forest plot of the VEGF-D expression level and incidence of LNM.

Figure 7: Funnel plot of literature publication bias.
proliferation of vascular endothelial cells and enhancement of vascular permeability and is strongly associated with tumor growth and metastasis. Its expression is therefore a key indicator for judging tumor types and prognosis [47, 48].

VEGF is a family in which VEGF-A can accelerate angiogenesis and increase the permeability of blood vessels [49]. VEGF-C and VEGF-D function in angiogenesis and new lymphatic vessels in cancer tissues [26]. Among them, VEGF-C mediates angiogenesis via VEGFR-2 and lymphangiogenesis via VEGFR-3, which are the key links in lymphatic metastasis [50]. We must admit that our study has certain limitations. First, the included studies were conducted over a large time span, and the improvement of detection methods inevitably impacts the detection results, which reduce the reliability of the study. Second, only LNM metastasis was used as the main indicator in the meta-analysis, and the differences in survival data between different factors were not compared, and thus the results might not be generalized. The literature included in this study has high heterogeneity, which may be related to the time span of the included literature. Whether it is the diagnosis method of Ki67 and VEGF, the treatment of NSCLC or the detection method of lymph node metastasis in NSCLC, it is constantly improving. Ki67 and VEGF have been the main targets of current NSCLC treatment, and different treatment regimens will have a significant impact on the expression of Ki67 and VEGF. Therefore, later analysis should be performed according to different inclusion times to determine whether different study times have an impact on the relationship between Ki67, VEGF, and lymph node metastasis in NSCLC. Future research will still need to potentially involve more reliable data and indicators.

5. Conclusion
In NSCLC patients, the high expression of Ki67, VEGF-A, and VEGF-C is associated with an increased risk of lymph node metastasis, while VEGF-D was not correlated with lymph node metastasis. The levels of Ki67, VEGF-A, and VEGF-C show great potential to anticipate the risk of lymph node metastasis. However, the prognosis is related to various factors such as the malignancy of the tumor, the treatment plan, and efficiency, whether the cancer cells are completely removed, the hospital’s prognostic measures, and the patient’s physical and psychological state. Therefore, the prognosis cannot be determined only by Ki67 and VEGF. In addition to paying attention to relevant tumor indicators, patient’s mentality, balanced diet, reasonable schedule, and scientific exercise are also required.

Data Availability
The datasets used during the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This research was supported by the Hebei Provincial Health Commission Key Science and Technology Research Program (no. 20200552).

References
[1] F. Wu, L. Wang, and C. Zhou, “Lung cancer in China: current and prospect,” Current Opinion in Oncology, vol. 33, no. 1, pp. 40–46, 2021.
[2] A. A. Thai, B. J. Solomon, L. V. Sequist, J. F. Gainor, and R. S. Heist, “Lung cancer,” The Lancet, vol. 398, no. 10299, pp. 535–554, 2021.
[3] B. C. Bade and C. S. Dela Cruz, “Lung cancer 2020,” Clinics in Chest Medicine, vol. 41, no. 1, pp. 1–24, 2020.
[4] R. Ruiz-Cordero and W. P. Devine, “Targeted therapy and checkpoint immunotherapy in lung cancer,” Surgical Pathology Clinics, vol. 13, no. 1, pp. 17–33, 2020.
[5] I. Tousmazis, M. Bastani, S. S. Han, and S. K. Plevritis, “Risk-based lung cancer screening: a systematic review,” Lung Cancer, vol. 147, pp. 154–186, 2020.
[6] R. S. Herbst, D. Morgenstern, and C. Boshoff, “The biology and management of non-small cell lung cancer,” Nature, vol. 553, no. 7689, pp. 446–454, 2018.
[7] C. M. Rudin, E. Brambilla, C. Fairen-Finn, and J. Sage, “Small-cell lung cancer,” Nature Reviews Disease Primers, vol. 7, no. 1, p. 3, 2021.
[8] Z. Wang, Y. Wu, L. Wang et al., “Predicting occult lymph node metastasis by nomogram in patients with lung adenocarcinoma ≤2 cm,” Future Oncology, vol. 17, no. 16, pp. 2005–2013, 2021.
[9] B. Jianlong, Z. Pinyi, W. Xiaohong et al., “Risk factors for lymph node metastasis and surgical scope in patients with cN0 non-small cell lung cancer: a single-center study in China,” Journal of Cardiothoracic Surgery, vol. 16, no. 1, p. 304, 2021.
[10] X. Sun and P. D. Kaufman, “Ki-67: more than a proliferation marker,” Chromosoma, vol. 127, no. 2, pp. 175–186, 2018.
[11] M. Sobecki, K. Mrouj, J. Colinge et al., “Cell-cycle regulation accounts for variability in ki-67 expression levels,” Cancer Research, vol. 77, no. 10, pp. 2722–2734, 2017.
[12] S. S. Menon, C. Guruvayoorappan, K. M. Sakhivel, and R. R. Rasm, “Ki-67 protein as a tumour proliferation marker,” Clinica Chimica Acta, vol. 491, pp. 39–43, 2019.
[13] R. S. Apte, D. S. Chen, and N. Ferrara, “VEGF in signaling and disease: beyond discovery and development,” Cell, vol. 176, no. 6, pp. 1248–1264, 2019.
[14] K. S. Siveen, K. Prabhu, R. Krishnankutty et al., “Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges,” Current Vascular Pharmacology, vol. 15, pp. 339–351, 2017.
[15] S. K. Riaz, Y. Iqbal, and M. F. A. Malik, “Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 5, pp. 1677–1682, 2015.
[16] T. Nagano, M. Tachihara, and Y. Nishimura, “Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer,” Current Cancer Drug Targets, vol. 19, no. 8, pp. 595–630, 2019.
[17] A. Del Gobbo, A. Pellegrinelli, G. Gaudioe et al., “Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas,” Histopathology, vol. 68, no. 5, pp. 746–751, 2016.
Evidence-Based Complementary and Alternative Medicine

[18] S. P. L. Saw and D. S. W. Tan, “Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future,” *Annals of Oncology*, vol. 32, no. 9, pp. 1075-1076, 2021.

[19] L. Y. He, H. Zhang, Z. K. Wang, and H. Z. Zhang, “Diagnostic and prognostic significance of E-cadherin and Ki-67 expression in non-small cell lung cancer patients,” *European Review for Medical and Pharmacological Sciences*, vol. 20, pp. 3812–3817, 2016.

[20] Y. Xue, X. Zang, Y. Liu et al., “Independent risk factors for lymph node metastasis in 2623 patients with non-small cell lung cancer,” *Surgical Oncology*, vol. 34, pp. 256–260, 2020.

[21] Y. Ji, M. Zheng, S. Ye, J. Chen, and Y. Chen, “PTEN and Ki-67 expression is associated with clinicopathologic features of non-small cell lung cancer,” *Journal of Biomedical Research*, vol. 28, pp. 462–467, 2014.

[22] J. Yang, N. Ramnath, K. B. Moysich et al., “Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer,” *BMC Cancer*, vol. 6, no. 1, p. 203, 2006.

[23] H. K. Ahn, M. Jung, S.-Y. Ha et al., “Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer,” *Tumor Biology*, vol. 35, no. 6, pp. 5735–5740, 2014.

[24] Y. Adachi, H. Nakamura, Y. Kitamura et al., “Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases,” *Pathology International*, vol. 57, no. 4, pp. 171–177, 2007.

[25] T. Donnem, K. Al-Shibli, S. Al-Saad, M. P. Delghandi, L.-T. Busund, and R. M. Bremnes, “VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells,” *Lung Cancer*, vol. 63, no. 2, pp. 277–283, 2009.

[26] Y. Feng, W. Wang, J. Hu, J. Ma, Y. Zhang, and J. Zhang, “Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer,” *The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology*, vol. 293, no. 5, pp. 802–812, 2010.

[27] X. Guo, Y. Chen, Z. Xu, Z. Xu, Y. Qian, and X. Yu, “Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer,” *Acta Biochimica et Biophysica Sinica*, vol. 41, no. 3, pp. 217–222, 2009.

[28] S. Ikawari, S. Nagai, H. Katakura et al., “D2-40-positive lymphatic vessel density is a poor prognostic factor in squamous cell carcinoma of the lung,” *Annals of Surgical Oncology*, vol. 16, no. 6, pp. 1678–1685, 2009.

[29] H. Kojima, N. Shijubo, G. Yamada et al., “Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma,” *Cancer*, vol. 104, no. 8, pp. 1668–1677, 2005.

[30] T. Nakashima, C. L. Huang, D. Liu et al., “Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer,” *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, vol. 10, pp. 157–165, 2004.

[31] E. Ogawa, K. Takenaka, K. Yanagihara et al., “Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients,” *British Journal of Cancer*, vol. 91, no. 3, pp. 498–503, 2004.

[32] F. Renyi-Vamos, J. Tovari, J. Fillinger et al., “Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer,” *Clinical Cancer Research*, vol. 11, no. 20, pp. 7344–7353, 2005.

[33] P. Saintigny, M. Kambouchner, M. Ly et al., “Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node,” *Lung Cancer*, vol. 58, no. 2, pp. 205–213, 2007.

[34] I. Takamaki, “Lymphatic microvessel density using D2-40 is associated with nodal metastasis in non-small cell lung cancer,” *Oncology Reports*, vol. 15, pp. 437–442, 2006.

[35] S. Zuo, Y. Ji, J. Wang, and J. Guo, “Expression and clinical implication of HIF-1α and VEGF-C in non-small cell lung cancer,” *Journal of Huazhong University of Science and Technology-Medical Sciences*, vol. 28, no. 6, pp. 674–676, 2008.

[36] M. M. Bi, B. Shang, Z. Wang, and G. Chen, “Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer,” *Thoracic Cancer*, vol. 8, no. 6, pp. 634–641, 2017.

[37] F. R. Hirsch, G. V. Scagliotti, J. L. Mulshine et al., “Lung cancer: current therapies and new targeted treatments,” *The Lancet*, vol. 389, no. 10066, pp. 299–311, 2017.

[38] L. Xia, Y. Liu, and Y. Wang, “PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions,” *The Oncologist*, vol. 24, no. S1, pp. 31–41, 2019.

[39] S. Wang, S. Zimmermann, K. Parikh, A. S. Mansfield, and A. A. Adjei, “Current diagnosis and management of small-cell lung cancer,” *Mayo Clinic Proceedings*, vol. 94, no. 8, pp. 1599–1622, 2019.

[40] A. H. El-Sherief, C. T. Lau, B. W. Carter, and C. C. Wu, “Staging lung cancer,” *Radiologic Clinics of North America*, vol. 56, no. 3, pp. 399–409, 2018.

[41] F. Celikoglu, S. I. Celikoglu, and E. P. Goldberg, “Intratumoural chemotherapy of lung cancer for diagnosis and treatment of draining lymph node metastasis,” *Journal of Pharmacy and Pharmacology*, vol. 62, no. 3, pp. 287–295, 2010.

[42] A. R. Dezube and M. T. Jaklitsch, “Minimizing residual occult nodal metastasis in NSCLC: recent advances, current status and controversies,” *Expert Review of Anticancer Therapy*, vol. 20, no. 2, pp. 117–130, 2020.

[43] J. N. Jakobsen and J. B. Sørensen, “Clinical impact of ki-67 grading and classification of neuroendocrine tumors,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 34, pp. 541–546, 2020.

[44] J. Y. Kim, S.-M. Hong, and J. Y. Ro, “Recent updates on grading and classification of neuroendocrine tumors,” *Annals of Diagnostic Pathology*, vol. 29, pp. 11–16, 2017.

[45] C. R. Lindsay, S. Le Moulec, F. Billiot et al., “Vimentin and Ki67 expression in circulating tumour cells derived from primary tumour and metastatic lymph node,” *Cancer*, vol. 79, no. 1, pp. 1–7, 2013.

[46] J. F. Xiong, Y. M. Lou, and L. Wang, “Expressions of Ki67 and Ki-67 in non-small cell lung cancer and their relationship with invasion and metastasis,” *Journal of Biomedical Research*, vol. 24, pp. 437–442, 2006.

[47] Y. Hisada and N. Mackman, “Tissue factor and cancer: regulation, tumor growth, and metastasis,” *Seminars in Thrombosis and Hemostasis*, vol. 45, no. 04, pp. 385–395, 2019.
[48] M. Alevizakos, S. Kaltsas, and K. N. Syrigos, “The VEGF pathway in lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 72, no. 6, pp. 1169–1181, 2013.

[49] W. Y. Jung, K.-W. Min, and Y. H. Oh, “Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients’ survival,” Scientific Reports, vol. 11, no. 1, p. 1321, 2021.

[50] S. Maekawa, A. Iwasaki, T. Shirakusa et al., “Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma,” Anticancer Research, vol. 27, pp. 3735–3741, 2007.